Does Medicare cover Wegovy (oral 25mg) in 2026?
Medicare is inconsistent on GLP-1 coverage for the weight-loss indication, and reliably covers GLP-1s prescribed for type 2 diabetes. Wegovy (oral 25mg) is not on their preferred formulary as of May 2026. Below is what to expect, what to ask, and your backup plan if denied. The CMS Medicare GLP-1 Bridge (July 1, 2026 through Dec 31, 2027) covers Wegovy, Foundayo, and Zepbound KwikPen at a flat $50/month for eligible enrollees in participating Part D plans. Outside the Bridge, federal law (Medicare Modernization Act of 2003) still excludes weight-loss-only drugs; diabetes-indicated drugs (Ozempic, Mounjaro) are covered with a qualifying diagnosis.
What you'll actually pay for Wegovy (oral 25mg) on Medicare
| Path | Monthly cost |
|---|---|
| Medicare GLP-1 Bridge tier | $50 flat |
| Medicare insurance + savings card | N/A |
| Medicare insurance, no savings card | $25–$100 |
| NovoCare self-pay (no insurance) | $149 |
| Branded telehealth (Hims/Ro/LifeMD) | $449 |
| Cash retail (full WAC) | $1,349 |
Medicare prior authorization requirements
Based on Medicare (Part D)'s public formulary documents and PBM coverage policies for Wegovy (oral 25mg) (and similar weight-loss GLP-1s) as of May 2026:
- GLP-1 Bridge tier: participating Part D plan + BMI criteria (no heart-disease documentation)
- Outside the Bridge: statute excludes weight-loss-only coverage
Coverage policies change frequently. Confirm against your specific plan's Summary of Benefits or by calling the member services number on your insurance card.
If Medicare denies your Wegovy (oral 25mg) prior auth
Three real options, in rough order of effort vs cost:
- Appeal the denial. Most denials are overturnable with the right documentation (BMI, comorbidity diagnosis, prior weight-loss attempts). Step-by-step appeal playbook.
- Switch to NovoCare self-pay at $149/month. No insurance involved; you pay the manufacturer directly. Visit NovoCare.
- Branded telehealth (Hims, Ro, LifeMD) at around $449/month. Includes prescriber visit; ships within days. Provider comparison.
Wegovy (oral 25mg) coverage on other major insurers
Other GLP-1s on Medicare
Frequently asked questions
How do I know if my specific Medicare plan covers Wegovy (oral 25mg)?
Coverage varies dramatically by employer plan within the same carrier. Call the member-services number on your Medicare insurance card and ask: "Is Wegovy (oral 25mg) covered on my formulary, what tier, and does it require prior authorization?" Get the answer in writing or via the member portal. Your plan's Summary of Benefits and Coverage (SBC) document also lists the formulary tier.
Can I use the Wegovy (oral 25mg) savings card with Medicare?
No. Medicare members are excluded from manufacturer savings cards by the federal anti-kickback statute, regardless of plan. The Medicare-specific path for Wegovy (oral 25mg) is the CMS Medicare GLP-1 Bridge (flat $50/month in participating Part D plans) - a CMS program, not manufacturer copay assistance, which is why it can legally reach Medicare beneficiaries.
What if Medicare requires step therapy before approving Wegovy (oral 25mg)?
Step therapy means trying (and failing) an older or cheaper drug first. Common step drugs for GLP-1s are phentermine, topiramate, or older Saxenda. If your prescriber documents medical reasons you cannot tolerate the step drug (or have a contraindication), they can request a step-therapy exception. This is a separate request from the prior auth and often succeeds when properly documented. Full appeal playbook here.
Is it worth paying out of pocket through NovoCare instead of fighting Medicare?
NovoCare self-pay is $149/month. If Medicare's expected out-of-pocket cost (after PA approval and savings card) is at or below this number, insurance is the better deal. If your plan denies coverage entirely or requires step therapy you cannot complete, NovoCare may be the faster path. The math gets clearer once you have either an approval or denial in hand.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.